Rubius injects new blood into red cell development program

Massachusetts, USA-based Rubius Therapeutics has shaken up its executive team, with new appointments in the firm’s medical, financial, legal and HR divisions.

The key post of chief medical officer will be held by Chris Carpenter, who most recently served as senior vice president and head of the cancer epigenetics department at GlaxoSmithKline (LSE: GSK).

At GSK, Dr Carpenter led the development of Votrient (pazopanib). In a previous role at America’s Merck & Co (NYSE: MRK) he developed the PARP inhibitor MK-4827, which later became Tesaro’s (Nasdaq: TSRO) Zejula (niraparib).